The long and short non-coding RNAs modulating EZH2 signaling in cancer
S Mirzaei, MH Gholami, K Hushmandi… - Journal of hematology & …, 2022 - Springer
Non-coding RNAs (ncRNAs) are a large family of RNA molecules with no capability in
encoding proteins. However, they participate in developmental and biological processes …
encoding proteins. However, they participate in developmental and biological processes …
Role of miR‑181a‑5p in cancer
MicroRNAs (miRNAs) are non‑coding RNAs (ncRNAs) that can post‑transcriptionally
suppress targeted genes. Dysregulated miRNAs are associated with a variety of diseases …
suppress targeted genes. Dysregulated miRNAs are associated with a variety of diseases …
tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression
K Panoutsopoulou, T Dreyer, J Dorn, E Obermayr… - Cancers, 2021 - mdpi.com
Simple Summary In the precision medicine era, epithelial ovarian cancer (EOC) is
characterized by a high death-to-incidence rate and poor 5-year survival. The identification …
characterized by a high death-to-incidence rate and poor 5-year survival. The identification …
Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics
M Chen, N Lei, W Tian, Y Li… - Therapeutic advances in …, 2022 - journals.sagepub.com
Ovarian cancer (OC) is the third most common gynecological malignancy with the highest
mortality worldwide. OC is usually diagnosed at an advanced stage, and the standard …
mortality worldwide. OC is usually diagnosed at an advanced stage, and the standard …
[HTML][HTML] tRNA-derived small RNA 3′ U-tRFValCAC promotes tumour migration and early progression in ovarian cancer
K Panoutsopoulou, P Magkou, T Dreyer, J Dorn… - European Journal of …, 2023 - Elsevier
Introduction Despite recent advances in epithelial ovarian cancer (EOC) management, the
highly heterogenous histological/molecular tumour background and patients' treatment …
highly heterogenous histological/molecular tumour background and patients' treatment …
miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome
MA Papadimitriou, AM Papanota… - British journal of …, 2022 - nature.com
Background Despite significant advances in multiple myeloma (MM) therapy, disease
relapse and treatment resistance remain major obstacles in clinical management. Herein …
relapse and treatment resistance remain major obstacles in clinical management. Herein …
Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer
Objectives In the era of precision medicine, the highly aggressive and heterogenous triple-
negative breast cancer (TNBC) is still characterized by limited options to support …
negative breast cancer (TNBC) is still characterized by limited options to support …
外泌体来源的miR-181a 促进胶质瘤的血管生成.
欧阳一彬， 何青龙， 孙衍昶， 莫业和… - Chinese Journal of …, 2021 - search.ebscohost.com
目的: 探讨外泌体来源的miR-181a 对胶质瘤血管生成和肿瘤进展的影响. 方法: 选用2017 年8
月至2019 年12 月海南医学院第二附属医院手术切除的83 例胶质瘤和13 例瘤旁组织标本 …
月至2019 年12 月海南医学院第二附属医院手术切除的83 例胶质瘤和13 例瘤旁组织标本 …
miR-181a-3p inhibits malignant biological behavior of non-small cell lung cancer via down-regulating RAD21 expression
H Li - Journal of comprehensive Molecular …, 2021 - … journals.publicknowledgeproject.org
Lung cancer is one of the most common malignant tumors in the world, and it has become
the first cause of death from malignant tumors in the Chinese urban population. Non-small …
the first cause of death from malignant tumors in the Chinese urban population. Non-small …
[PDF][PDF] miR-181a及miR-138对软骨肉瘤细胞增殖的影响*
曾旭凯， 何畔， 汪志军 - 医学临床研究 - journal07.magtech.org.cn
[目的] 探讨miR-181a 及miR-138 对软骨肉瘤细胞增殖的影响.[方法] 收集20 例软骨瘤及20
例软骨肉瘤组织标本, 采用qRT-PCR 检测miR-181a 及miR-138 表达水平, 采用miRNA …
例软骨肉瘤组织标本, 采用qRT-PCR 检测miR-181a 及miR-138 表达水平, 采用miRNA …